enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. GSK shares tumble 9% after 70,000 Zantac lawsuits ... - AOL

    www.aol.com/news/gsk-shares-tumble-9-70...

    (Reuters) -Shares of British drugmaker GSK dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer ...

  3. GSK wins latest trial over Zantac cancer claims - AOL

    www.aol.com/news/gsk-wins-latest-trial-over...

    GSK won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman's illness, a company ...

  4. GSK whistleblower claims drugmaker cheated US government over ...

    www.aol.com/news/gsk-faces-whistleblower-lawsuit...

    (Reuters) -GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a ...

  5. GSK settles another Zantac lawsuit in California - AOL

    www.aol.com/news/gsk-confidentially-settles...

    (Reuters) -GSK said on Thursday it had agreed to settle another lawsuit in California that alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to ...

  6. GSK settles two California lawsuits related to heartburn drug ...

    www.aol.com/news/gsk-settles-two-california...

    Former Zantac makers GSK, Pfizer, Sanofi and Boehringer Ingelheim are facing about 4,000 claims in California state court and about 2,000 in various other state courts around the country.

  7. GSK shares slide after US health agency narrows scope ... - AOL

    www.aol.com/news/gsk-shares-slide-us-health...

    (Reuters) -GSK shares fell as much as 7% on Thursday, a day after a U.S. public health agency narrowed its age recommendation for use of respiratory syncytial virus (RSV) vaccines and did not ...

  8. GSK shares fall after sales of top two vaccines disappoint - AOL

    www.aol.com/news/gsk-raises-annual-profit-sales...

    British drugmaker GSK cut its forecast for 2024 vaccine sales on Wednesday after quarterly revenue from its blockbuster shingles and respiratory syncytial virus (RSV) jabs missed expectations ...

  9. GSK lifts growth target for HIV business on demand for long ...

    www.aol.com/news/gsk-lifts-growth-ambitions-hiv...

    GSK also said that patent protection for its best-selling antiviral ingredient dolutegravir, which is used in HIV drugs and had a combined 1.3 billion pounds in second-quarter sales, would expire ...